Future Pipeline
With its industrial platform now established, Biotis is shifting from emergency response to long-term growth. The next phase focuses on expanding into high-impact vaccines and advanced biologics that will define Indonesia and ASEAN health security over the next decade
Expansion & Localization
Our immediate focus stabilizes national health security by scaling pediatric and combination vaccines. We are optimizing production for PCV and Pentavalent vaccines while introducing critical preventions for Hepatitis B, HPV, and Rotavirus.
Formulation & Fill-Finish
Increasing domestic localization through advanced packaging and finishing capabilities.
Capacity Scaling
Expanding existing infrastructure to meet 100% of national pediatric demand.
Regional Supply &
Integration
Shifting from domestic supply to regional leadership. This phase emphasizes high-level technology transfer and greater upstream localization for advanced vaccine platforms.
ASEAN Markets
Expanding our logistical network to provide affordable vaccines across Southeast Asia.
Tech Transfer
Deepening upstream capabilities with mRNA and vector-based technologies.
Innovative Biologics
Establishing Indonesia as a global force in the next generation of medicine. Our long-term vision focuses on innovative biologics and immunotherapies that treat previously intractable diseases.
Next-Gen Biologics
Protein-based therapeutics and monoclonal antibodies.
Immunotherapy
Personalized cell therapies and cancer treatment breakthroughs.
Global Hub
Achieving full-scale independent manufacturing for global distribution.